Equities research analysts forecast that MacroGenics Inc (NASDAQ:MGNX) will report ($0.95) earnings per share for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for MacroGenics’ earnings. The highest EPS estimate is ($0.37) and the lowest is ($1.27). MacroGenics posted earnings of ($1.34) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 29.1%. The firm is scheduled to report its next quarterly earnings results on Monday, May 6th.

On average, analysts expect that MacroGenics will report full-year earnings of ($3.75) per share for the current fiscal year, with EPS estimates ranging from ($5.18) to ($1.81). For the next year, analysts forecast that the firm will report earnings of ($4.20) per share, with EPS estimates ranging from ($5.49) to ($2.52). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover MacroGenics.

A number of brokerages recently commented on MGNX. Wedbush reaffirmed a “positive” rating and set a $20.00 price objective (down from $44.00) on shares of MacroGenics in a research report on Tuesday, January 22nd. They noted that the move was a valuation call. ValuEngine raised shares of MacroGenics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 7th. Zacks Investment Research downgraded shares of MacroGenics from a “buy” rating to a “hold” rating in a research report on Friday, March 1st. HC Wainwright set a $39.00 price objective on shares of MacroGenics and gave the company a “buy” rating in a research report on Wednesday, February 20th. Finally, Nomura boosted their price objective on shares of MacroGenics from $41.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, February 7th. One research analyst has rated the stock with a sell rating, six have given a hold rating and seven have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $31.78.

In other MacroGenics news, Director Matthew K. Fust sold 6,924 shares of MacroGenics stock in a transaction that occurred on Wednesday, February 6th. The shares were sold at an average price of $29.38, for a total value of $203,427.12. Following the completion of the sale, the director now directly owns 7,424 shares in the company, valued at $218,117.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Thomas Spitznagel sold 1,770 shares of MacroGenics stock in a transaction that occurred on Wednesday, February 6th. The shares were sold at an average price of $30.00, for a total transaction of $53,100.00. Following the completion of the sale, the senior vice president now owns 1,770 shares of the company’s stock, valued at $53,100. The disclosure for this sale can be found here. Insiders sold 8,762 shares of company stock valued at $258,567 over the last quarter. Corporate insiders own 8.82% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of MGNX. BlackRock Inc. lifted its stake in MacroGenics by 3.3% in the third quarter. BlackRock Inc. now owns 3,225,256 shares of the biopharmaceutical company’s stock valued at $69,150,000 after acquiring an additional 103,189 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in MacroGenics by 101.6% in the third quarter. Dimensional Fund Advisors LP now owns 582,511 shares of the biopharmaceutical company’s stock valued at $12,489,000 after acquiring an additional 293,527 shares during the last quarter. Allianz Asset Management GmbH lifted its stake in shares of MacroGenics by 9.2% in the third quarter. Allianz Asset Management GmbH now owns 104,511 shares of the biopharmaceutical company’s stock worth $2,241,000 after buying an additional 8,824 shares during the last quarter. Bailard Inc. acquired a new stake in shares of MacroGenics in the third quarter worth $270,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of MacroGenics in the third quarter worth $250,000. Hedge funds and other institutional investors own 75.39% of the company’s stock.

MGNX traded up $0.08 on Wednesday, reaching $17.49. 389,800 shares of the company traded hands, compared to its average volume of 1,339,385. MacroGenics has a 52-week low of $9.87 and a 52-week high of $32.32. The company has a market capitalization of $856.44 million, a PE ratio of -4.17 and a beta of 2.99.

About MacroGenics

MacroGenics, Inc, a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers.

Featured Story: What is a Special Dividend?

Get a free copy of the Zacks research report on MacroGenics (MGNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.